» Articles » PMID: 15246204

Impairment of CD4(+)CD25(+) Regulatory T-cells in Autoimmune Liver Disease

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2004 Jul 13
PMID 15246204
Citations 139
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: CD4(+) lymphocytes constitutively expressing the IL-2-receptor alpha-chain (CD25) regulate the activation of CD4 and CD8 autoreactive T-cells by suppressing their proliferation and effector function. The aim of this study is to: (1) measure the percentage of CD4(+)CD25(+) T-cells (T-regs) in patients with autoimmune liver disease at presentation and during remission, (2) correlate their frequency with disease activity, (3) determine their ability to expand and (4) to inhibit interferon-gamma (IFNgamma) production by CD4(+)CD25- T-cells.

Methods: 41 patients were studied. Percentage of T-regs was determined on peripheral blood mononuclear cells (PBMCs) by triple-colour flow cytometry; their ability to expand by exposing PBMCs to a T-cell expander (CD3/CD28 Dynabeads); their immunoregulatory function by measuring their ability to suppress IFNgamma production by CD4(+)CD25(-) T-cells.

Results: T-regs were significantly less in patients than in controls, and at diagnosis than during remission. Their percentage was inversely correlated with titres of anti-liver kidney microsomal and soluble liver antigen autoantibodies. T-regs ability to expand was significantly lower in patients than in controls, but that to suppress IFNgamma production by CD4(+)CD25(-) T-cells was maintained.

Conclusions: Decreased T-regs numbers and ability to expand may favour the emergence of liver-targeted autoimmunity, despite preserved suppressor function. Treatment should aim at increasing T-regs number.

Citing Articles

Clonal analysis of SepSecS-specific B and T cells in autoimmune hepatitis.

Kramer M, Mele F, Jovic S, Fernandez B, Jarrossay D, Low J J Clin Invest. 2025; 135(2.

PMID: 39817450 PMC: 11735102. DOI: 10.1172/JCI183776.


B and T cells: (Still) the dominant orchestrators in autoimmune hepatitis.

Longhi M, Zhang L, Mieli-Vergani G, Vergani D Autoimmun Rev. 2024; 23(7-8):103591.

PMID: 39117005 PMC: 11409799. DOI: 10.1016/j.autrev.2024.103591.


Characteristics of peripheral blood mononuclear cells and potential related molecular mechanisms in patients with autoimmune hepatitis: a single-cell RNA sequencing analysis.

Abe K, Abe N, Sugaya T, Takahata Y, Fujita M, Hayashi M Med Mol Morphol. 2024; 57(2):110-123.

PMID: 38340154 DOI: 10.1007/s00795-024-00380-5.


Silencing of aryl hydrocarbon receptor repressor restrains Th17 cell immunity in autoimmune hepatitis.

Gao L, Zhang W, Zhang L, Gromova B, Chen G, Csizmadia E J Autoimmun. 2023; 143:103162.

PMID: 38142533 PMC: 10981568. DOI: 10.1016/j.jaut.2023.103162.


sFgl2 gene-modified MSCs regulate the differentiation of CD4 T cells in the treatment of autoimmune hepatitis.

Ji W, Wang W, Li P, Liu Y, Zhang B, Qi F Stem Cell Res Ther. 2023; 14(1):316.

PMID: 37924141 PMC: 10625288. DOI: 10.1186/s13287-023-03550-x.